A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Survivors facing new medical concerns may fear the unknown, but perseverance is possible as they navigate unexpected ...

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

We were barely through with the first week of the New Year when the weather began to get ugly. Listening to weather reports, ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...